Enhanced proliferation inhibition and apoptosis in glioma cells elicited by combination of irinotecan and imatinib
- 1 May 2020
- journal article
- research article
- Published by Elsevier in European Journal of Pharmacology
- Vol. 874, 173022
Abstract
No abstract availableKeywords
Funding Information
- National Natural Science Foundation of China (81673522, 81872936)
This publication has 37 references indexed in Scilit:
- A Phase II study of pulse dose imatinib mesylate and weekly paclitaxel in patients aged 70 and over with advanced non-small cell lung cancerBMC Cancer, 2012
- Phase I study of sunitinib and irinotecan for patients with recurrent malignant gliomaJournal of Neuro-Oncology, 2011
- p21 in cancer: intricate networks and multiple activitiesNature Reviews Cancer, 2009
- Phase II Study of Imatinib in Patients With Recurrent Gliomas of Various Histologies: A European Organisation for Research and Treatment of Cancer Brain Tumor Group StudyJournal of Clinical Oncology, 2008
- Inhibition of autophagy at a late stage enhances imatinib‐induced cytotoxicity in human malignant glioma cellsInternational Journal of Cancer, 2008
- Sulforhodamine B colorimetric assay for cytotoxicity screeningNature Protocols, 2006
- Imatinib Mesylate Is a Potent Inhibitor of the ABCG2 (BCRP) Transporter and Reverses Resistance to Topotecan and SN-38 in Vitro Cancer Research, 2004
- Combination therapy with irinotecan and protein kinase C inhibitors in malignant gliomaCancer, 2003
- Low concentrations of paclitaxel induce cell type-dependent p53, p21 and G1/G2 arrest instead of mitotic arrest: molecular determinants of paclitaxel-induced cytotoxicityOncogene, 2001
- The relevance of p53 mutation in urological malignancies: possible clinical implications for bladder cancerBritish Journal of Urology, 1996